# PIVOT-02 (NCT02983045)

> A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors

No report yet. It can be ordered.

- Drugs tested: bempegaldesleukin plus nivolumab; bempegaldesleukin plus nivolumab plus ipilimumab
- Indication: locally advanced or metastatic solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02983045
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Nektar Therapeutics
- Conditions: Melanoma; Renal Cell Carcinoma; Non Small Cell Lung Cancer; Urothelial Carcinoma; Triple Negative Breast Cancer; HR+/HER2- Breast Cancer; Gastric Cancer
- Interventions: Dose Escalation Doublet: Combination of NKTR-214 + nivolumab; Dose Expansion Doublet: Combination of NKTR-214 + nivolumab; Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab; Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
- Enrollment: 557
- Primary outcome: Part 1 Dose Escalation: Incidence of Dose-limiting Toxicity (DLT) During the DLT Evaluation Window
- Primary outcome: Part 3 Schedule Finding: Incidence of Dose-limiting Toxicity (DLT) During the DLT Evaluation Window
- Primary outcome: Part 2 and Part 4: Objective Response Rate (ORR) Per RECIST 1.1 at Recommended Phase 2 Dose (RP2D)

## Indexed commentary on PIVOT-02 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X
- 1 YouTube video
- 1 podcast episode

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=pivot-02-nct02983045